Supply of Valsartan/Hydrochlorothiazide 160-12.5 mg Tablets (90-count bottles)

The contract requires the manufacture, labeling, packaging, and delivery of FDA-approved generic Valsartan/Hydrochlorothiazide 160-12.5 mg tablets in 90-count bottles, fully compliant with current good manufacturing practices, the Drug Supply Chain Security Act, and all federal labeling requirements. Production must include precise barcoding to ensure compatibility with automated dispensing systems and adherence to quarterly reporting obligations for regulatory and inventory tracking purposes. The product must meet all pharmaceutical quality benchmarks and be distributed under strict regulatory oversight to ensure patient safety and supply chain integrity. This subcontract is issued by the Department of Defense through DLA Troop Support, with a posted date of July 13, 2026, and a response deadline of August 13, 2026. The NAICS code 325412 confirms the activity falls under pharmaceutical and medicine manufacturing. There is no designated set-aside classification, and performance location details are unspecified, though the end-use is tied to federal healthcare logistics. All work must be completed in accordance with federal procurement and pharmaceutical standards, with no deviations permitted in formulation, labeling, or packaging protocols.